Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Aquatic Capital Management LLC

Aquatic Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 80.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 169,394 shares of the biotechnology company's stock after purchasing an additional 75,776 shares during the quarter. Aquatic Capital Management LLC owned about 0.14% of Arrowhead Pharmaceuticals worth $3,185,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ARWR. R Squared Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $38,000. Van ECK Associates Corp boosted its stake in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV grew its position in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $190,000. Finally, First Citizens Bank & Trust Co. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $205,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on ARWR shares. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley restated a "buy" rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $41.44.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the sale, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at approximately $64,230,110.04. This trade represents a 3.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 275,880 shares of company stock valued at $4,034,037 over the last quarter. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR traded up $0.38 during midday trading on Friday, hitting $14.42. 1,397,083 shares of the stock were exchanged, compared to its average volume of 1,448,960. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a 50 day moving average price of $14.06 and a 200-day moving average price of $18.27. The stock has a market cap of $1.98 billion, a P/E ratio of -2.79 and a beta of 0.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.